Piramal acquires Cipla's OTC contraceptive brand `i-pill' for Rs95 crore
23 Mar 2010
Piramal Healthcare Limited today signed an agreement with Cipla Limited to purchase all intellectual property rights in India related to `i-pill' for the brand for a total consideration of Rs95 crore.
The acquisition of "i-pill" strengthens Piramal's over the counter (OTC) portfolio, which has strong consumer brands such as Lacto Calamine skin care range, Supractiv Complete, Saridon and Polycrol antacid.
I-pill is an emergency contraceptive pill (ECP) used to prevent unplanned pregnancy and is available over the counter at local chemists. It is not an abortion pill.
I-pill features in the top-300 pharmaceutical products and had sales of Rs30.9 crore in the last 12 months, as per ORG IMS.
The feminine contraceptive contains Levonorgestrel, a progestogen that helps prevent unwanted pregnancies if taken within 72 hours of unprotected sex. "i-pill" has no long term or serious side effects and is safe to use for almost every woman except those who are allergic to evonorgestrel.
I-pill has been instrumental in building awareness about the emergency contraceptive pill category in India.
.jpg "RBI keeps repo rate unchanged as focus remains on inflation")
.jpg "Indian Oil, Panasonic team up for lithium-ion cell production in India")
